Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells

Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminoc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology and applied pharmacology 2013-05, Vol.269 (1), p.17-24
Hauptverfasser: Bao, Yizhong, Wang, Dan, Li, Zhiming, Hu, Yuxing, Xu, Aihong, Wang, Quanrui, Shao, Chunlin, Chen, Honghong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 24
container_issue 1
container_start_page 17
container_title Toxicology and applied pharmacology
container_volume 269
creator Bao, Yizhong
Wang, Dan
Li, Zhiming
Hu, Yuxing
Xu, Aihong
Wang, Quanrui
Shao, Chunlin
Chen, Honghong
description Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3. ► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.
doi_str_mv 10.1016/j.taap.2013.02.010
format Article
fullrecord <record><control><sourceid>pubmed_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22285292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X1300080X</els_id><sourcerecordid>23454449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</originalsourceid><addsrcrecordid>eNp9kM9u1DAQhy1ERZeWF-CALKEeE8b_dmOJC12VFlGpHKjEzZo49tarxFnZ2ZX6BLw2TreFGyePPN9vNPMR8p5BzYAtP23rCXFXc2CiBl4Dg1dkwUAvKxBCvCYLAMkqgObXKXmb8xYAtJTsDTnlQioppV6Q31feB4v2kY6eIo3jwfXUPrgepzHRyx_ry2vqS5XcMB5C3NB9whj2A8XY0V0aJ2en-Rs3GGKeXtpViN3euq7kIpaBru9phwNuHA2RJpzy04Cb7xV_auZzcuKxz-7d83tG7r9e_VzfVLd319_WX24rK5mcKr6Usmkt10xwrqwUVi-1Q68Us8A7dFqA4xa08myFSjWqXNwqodpVqz024ox8PM4d8xRMtqEc8GDHGMsdhnPeKK55ofiRsmnMOTlvdikMmB4NAzO7N1szuzezewPcFPcl9OEY2u3bwXV_Iy-yC3DxDGC22Puiyob8j1sJ1cBKFe7zkXNFxCG4NO_pYtEZ0rxmN4b_7fEHKPahhQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</creator><creatorcontrib>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</creatorcontrib><description>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3. ► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2013.02.010</identifier><identifier>PMID: 23454449</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Animals ; Biological and medical sciences ; Biological effects of radiation ; Biomarkers - blood ; Body Burden ; Cell Line ; Chelating agents ; Chelating Agents - administration &amp; dosage ; Chelating Agents - pharmacology ; Chelation Therapy - methods ; CREATININE ; Creatinine - blood ; Cytoprotection ; DEPLETED URANIUM ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; DTPA ; EXCRETION ; Fundamental and applied biological sciences. Psychology ; Glycine - administration &amp; dosage ; Glycine - analogs &amp; derivatives ; Glycine - pharmacology ; HK-2 cell line ; Humans ; INJECTION ; Injections ; Ionizing radiations ; Kidney Diseases - blood ; Kidney Diseases - chemically induced ; Kidney Diseases - pathology ; Kidney Diseases - prevention &amp; control ; Kidney Tubules - drug effects ; Kidney Tubules - metabolism ; Kidney Tubules - pathology ; KIDNEYS ; L-Lactate Dehydrogenase - metabolism ; LACTATE DEHYDROGENASE ; Male ; Mechanism ; Medical sciences ; Micronuclei, Chromosome-Defective - chemically induced ; Micronuclei, Chromosome-Defective - drug effects ; Organometallic Compounds ; Pentetic Acid - pharmacology ; RATS ; Rats, Sprague-Dawley ; Reactive Oxygen Species - metabolism ; Time Factors ; Tissues, organs and organisms biophysics ; Toxicology ; Uranium decorporation ; Urea - blood ; URINE</subject><ispartof>Toxicology and applied pharmacology, 2013-05, Vol.269 (1), p.17-24</ispartof><rights>2013 Elsevier Inc.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</citedby><cites>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041008X1300080X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27358075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23454449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22285292$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Bao, Yizhong</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Li, Zhiming</creatorcontrib><creatorcontrib>Hu, Yuxing</creatorcontrib><creatorcontrib>Xu, Aihong</creatorcontrib><creatorcontrib>Wang, Quanrui</creatorcontrib><creatorcontrib>Shao, Chunlin</creatorcontrib><creatorcontrib>Chen, Honghong</creatorcontrib><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3. ► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biological effects of radiation</subject><subject>Biomarkers - blood</subject><subject>Body Burden</subject><subject>Cell Line</subject><subject>Chelating agents</subject><subject>Chelating Agents - administration &amp; dosage</subject><subject>Chelating Agents - pharmacology</subject><subject>Chelation Therapy - methods</subject><subject>CREATININE</subject><subject>Creatinine - blood</subject><subject>Cytoprotection</subject><subject>DEPLETED URANIUM</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>DTPA</subject><subject>EXCRETION</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycine - administration &amp; dosage</subject><subject>Glycine - analogs &amp; derivatives</subject><subject>Glycine - pharmacology</subject><subject>HK-2 cell line</subject><subject>Humans</subject><subject>INJECTION</subject><subject>Injections</subject><subject>Ionizing radiations</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Diseases - pathology</subject><subject>Kidney Diseases - prevention &amp; control</subject><subject>Kidney Tubules - drug effects</subject><subject>Kidney Tubules - metabolism</subject><subject>Kidney Tubules - pathology</subject><subject>KIDNEYS</subject><subject>L-Lactate Dehydrogenase - metabolism</subject><subject>LACTATE DEHYDROGENASE</subject><subject>Male</subject><subject>Mechanism</subject><subject>Medical sciences</subject><subject>Micronuclei, Chromosome-Defective - chemically induced</subject><subject>Micronuclei, Chromosome-Defective - drug effects</subject><subject>Organometallic Compounds</subject><subject>Pentetic Acid - pharmacology</subject><subject>RATS</subject><subject>Rats, Sprague-Dawley</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Time Factors</subject><subject>Tissues, organs and organisms biophysics</subject><subject>Toxicology</subject><subject>Uranium decorporation</subject><subject>Urea - blood</subject><subject>URINE</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9u1DAQhy1ERZeWF-CALKEeE8b_dmOJC12VFlGpHKjEzZo49tarxFnZ2ZX6BLw2TreFGyePPN9vNPMR8p5BzYAtP23rCXFXc2CiBl4Dg1dkwUAvKxBCvCYLAMkqgObXKXmb8xYAtJTsDTnlQioppV6Q31feB4v2kY6eIo3jwfXUPrgepzHRyx_ry2vqS5XcMB5C3NB9whj2A8XY0V0aJ2en-Rs3GGKeXtpViN3euq7kIpaBru9phwNuHA2RJpzy04Cb7xV_auZzcuKxz-7d83tG7r9e_VzfVLd319_WX24rK5mcKr6Usmkt10xwrqwUVi-1Q68Us8A7dFqA4xa08myFSjWqXNwqodpVqz024ox8PM4d8xRMtqEc8GDHGMsdhnPeKK55ofiRsmnMOTlvdikMmB4NAzO7N1szuzezewPcFPcl9OEY2u3bwXV_Iy-yC3DxDGC22Puiyob8j1sJ1cBKFe7zkXNFxCG4NO_pYtEZ0rxmN4b_7fEHKPahhQ</recordid><startdate>20130515</startdate><enddate>20130515</enddate><creator>Bao, Yizhong</creator><creator>Wang, Dan</creator><creator>Li, Zhiming</creator><creator>Hu, Yuxing</creator><creator>Xu, Aihong</creator><creator>Wang, Quanrui</creator><creator>Shao, Chunlin</creator><creator>Chen, Honghong</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20130515</creationdate><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><author>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biological effects of radiation</topic><topic>Biomarkers - blood</topic><topic>Body Burden</topic><topic>Cell Line</topic><topic>Chelating agents</topic><topic>Chelating Agents - administration &amp; dosage</topic><topic>Chelating Agents - pharmacology</topic><topic>Chelation Therapy - methods</topic><topic>CREATININE</topic><topic>Creatinine - blood</topic><topic>Cytoprotection</topic><topic>DEPLETED URANIUM</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>DTPA</topic><topic>EXCRETION</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycine - administration &amp; dosage</topic><topic>Glycine - analogs &amp; derivatives</topic><topic>Glycine - pharmacology</topic><topic>HK-2 cell line</topic><topic>Humans</topic><topic>INJECTION</topic><topic>Injections</topic><topic>Ionizing radiations</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Diseases - pathology</topic><topic>Kidney Diseases - prevention &amp; control</topic><topic>Kidney Tubules - drug effects</topic><topic>Kidney Tubules - metabolism</topic><topic>Kidney Tubules - pathology</topic><topic>KIDNEYS</topic><topic>L-Lactate Dehydrogenase - metabolism</topic><topic>LACTATE DEHYDROGENASE</topic><topic>Male</topic><topic>Mechanism</topic><topic>Medical sciences</topic><topic>Micronuclei, Chromosome-Defective - chemically induced</topic><topic>Micronuclei, Chromosome-Defective - drug effects</topic><topic>Organometallic Compounds</topic><topic>Pentetic Acid - pharmacology</topic><topic>RATS</topic><topic>Rats, Sprague-Dawley</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Time Factors</topic><topic>Tissues, organs and organisms biophysics</topic><topic>Toxicology</topic><topic>Uranium decorporation</topic><topic>Urea - blood</topic><topic>URINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bao, Yizhong</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Li, Zhiming</creatorcontrib><creatorcontrib>Hu, Yuxing</creatorcontrib><creatorcontrib>Xu, Aihong</creatorcontrib><creatorcontrib>Wang, Quanrui</creatorcontrib><creatorcontrib>Shao, Chunlin</creatorcontrib><creatorcontrib>Chen, Honghong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bao, Yizhong</au><au>Wang, Dan</au><au>Li, Zhiming</au><au>Hu, Yuxing</au><au>Xu, Aihong</au><au>Wang, Quanrui</au><au>Shao, Chunlin</au><au>Chen, Honghong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2013-05-15</date><risdate>2013</risdate><volume>269</volume><issue>1</issue><spage>17</spage><epage>24</epage><pages>17-24</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3. ► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23454449</pmid><doi>10.1016/j.taap.2013.02.010</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-008X
ispartof Toxicology and applied pharmacology, 2013-05, Vol.269 (1), p.17-24
issn 0041-008X
1096-0333
language eng
recordid cdi_osti_scitechconnect_22285292
source MEDLINE; Elsevier ScienceDirect Journals
subjects 60 APPLIED LIFE SCIENCES
Animals
Biological and medical sciences
Biological effects of radiation
Biomarkers - blood
Body Burden
Cell Line
Chelating agents
Chelating Agents - administration & dosage
Chelating Agents - pharmacology
Chelation Therapy - methods
CREATININE
Creatinine - blood
Cytoprotection
DEPLETED URANIUM
Dose-Response Relationship, Drug
Drug Administration Schedule
DTPA
EXCRETION
Fundamental and applied biological sciences. Psychology
Glycine - administration & dosage
Glycine - analogs & derivatives
Glycine - pharmacology
HK-2 cell line
Humans
INJECTION
Injections
Ionizing radiations
Kidney Diseases - blood
Kidney Diseases - chemically induced
Kidney Diseases - pathology
Kidney Diseases - prevention & control
Kidney Tubules - drug effects
Kidney Tubules - metabolism
Kidney Tubules - pathology
KIDNEYS
L-Lactate Dehydrogenase - metabolism
LACTATE DEHYDROGENASE
Male
Mechanism
Medical sciences
Micronuclei, Chromosome-Defective - chemically induced
Micronuclei, Chromosome-Defective - drug effects
Organometallic Compounds
Pentetic Acid - pharmacology
RATS
Rats, Sprague-Dawley
Reactive Oxygen Species - metabolism
Time Factors
Tissues, organs and organisms biophysics
Toxicology
Uranium decorporation
Urea - blood
URINE
title Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20a%20novel%20chelator%20BPCBG%20for%20removing%20uranium%20and%20protecting%20against%20uranium-induced%20renal%20cell%20damage%20in%20rats%20and%20HK-2%20cells&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Bao,%20Yizhong&rft.date=2013-05-15&rft.volume=269&rft.issue=1&rft.spage=17&rft.epage=24&rft.pages=17-24&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2013.02.010&rft_dat=%3Cpubmed_osti_%3E23454449%3C/pubmed_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23454449&rft_els_id=S0041008X1300080X&rfr_iscdi=true